AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Pulmonary Arterial Hypertension

Recent research efforts aimed at curing Pulmonary Arterial Hypertension.

Last updated

Pulmonary Arterial Hypertension

Overview

Pulmonary arterial hypertension (PAH) is a rare form of high blood pressure in the arteries that carry blood from the heart to the lungs. The small lung arteries become narrowed, stiff, and structurally remodeled, forcing the right side of the heart to work harder and eventually risking right-heart failure. PAH includes idiopathic disease, inherited forms—often involving the BMPR2 gene—and cases associated with connective-tissue disease, congenital heart disease, drugs or toxins, HIV, portal hypertension, and other conditions. 2022 ESC/ERS Guidelines

PAH remains a serious, life-shortening illness, although outcomes have improved substantially with earlier diagnosis, specialty care, and combination treatment. Current standard care uses risk-guided combinations of medicines acting on the endothelin, nitric-oxide, and prostacyclin pathways; patients who remain at high risk despite optimized therapy may need intravenous or subcutaneous prostacyclin and referral for lung-transplant evaluation. 2022 ESC/ERS Guidelines Modern-era mortality registry

Scope of Recent Research (2020–present)

Research since 2020 has become notably more focused on reversing—not merely dilating—abnormal pulmonary vessels. Major questions are whether restoring bone morphogenetic protein (BMP) signaling, suppressing inappropriate cell growth and inflammation, correcting disease-causing gene defects, or regenerating damaged lung-vessel cells can produce durable reversal of PAH. Sotatercept has established that targeting disease biology beyond vasodilation can improve major clinical outcomes, but no available therapy has demonstrated a permanent cure or eliminated the need for continued monitoring and treatment. Sotatercept phase 3 trial Emerging PAH therapeutic landscape

Major Breakthroughs and Emerging Therapies

The clearest clinical breakthrough is sotatercept (Winrevair), an injected “ligand trap” that binds activins and related growth factors to rebalance abnormal activin/BMP signaling implicated in vascular-cell proliferation and remodeling. In the phase 3 STELLAR trial, adding sotatercept to stable background PAH therapy improved six-minute walking distance by a median treatment difference of 40.8 meters at 24 weeks and improved several secondary clinical measures. STELLAR trial The FDA approved sotatercept for adults with WHO Group 1 PAH on March 26, 2024; this was a major disease-modifying advance, but it is not a cure. FDA Winrevair snapshot

A second strategy is anti-proliferative small-molecule therapy. Inhaled seralutinib inhibits platelet-derived growth factor receptor, colony-stimulating factor 1 receptor, and c-KIT—kinases that promote inflammation, fibrosis, and excessive vascular-cell growth. The randomized phase 2 TORREY trial found a significant reduction in pulmonary vascular resistance after 24 weeks, supporting the idea that locally delivered kinase inhibition may help reverse vascular remodeling while limiting whole-body exposure. TORREY phase 2 trial This approach remains experimental, and whether it improves long-term survival or enables treatment withdrawal is not yet known. PROSERA phase 3 study

Gene replacement and RNA medicines are among the most cure-oriented preclinical approaches because reduced BMP receptor type 2 (BMPR2) signaling is a central cause of heritable PAH and is also disrupted in many non-inherited cases. In 2025, investigators used lung-endothelium-targeting lipid nanoparticles to deliver BMPR2 messenger RNA in two established rat models; treatment replenished BMPR2 protein, activated downstream signaling, improved pulmonary pressures, and reversed structural remodeling of lung vessels. BMPR2 mRNA nanoparticle study This is an important proof of concept for repeat-dose, nonviral gene replacement, but it has not yet entered human trials.

Gene editing is presently more valuable as a research-enabling platform than as a human PAH treatment. A 2026 study created sheep with a heterozygous edited BMPR2 defect, producing a large-animal model of heritable PAH that could help test delivery, safety, and durability of future gene-restoration strategies. Gene-edited BMPR2 sheep model Other RNA approaches, including microRNA inhibitors or replacement molecules and circular RNAs intended to normalize metabolism and vascular-cell behavior, have shown reversal-like effects in animal models but remain far from clinical validation. Circular-RNA therapy study

Clinical Trials and Experimental Approaches

Sotatercept has rapidly generated the strongest late-stage evidence in the field. STELLAR was a phase 3 trial in 323 adults with functional class II or III PAH receiving background treatment. STELLAR trial record In the 2025 phase 3 ZENITH trial, sotatercept added to maximal tolerated therapy reduced the risk of the composite outcome of death from any cause, lung transplantation, or PAH-worsening hospitalization by 76% in patients at high risk of death; the study was stopped early for efficacy. ZENITH trial In HYPERION, a phase 3 study in people diagnosed within the prior year and at intermediate or high risk, sotatercept reduced clinical-worsening events by 76% versus placebo in reported results. HYPERION trial report

Gossamer Bio’s inhaled seralutinib advanced from the positive phase 2 TORREY study to the phase 3 PROSERA trial. PROSERA enrolled 390 participants, completed in December 2025, and was designed to assess exercise capacity and time to clinical worsening; as of its May 2026 registry update, results had not been posted. PROSERA phase 3 study The trial illustrates the field’s effort to test whether direct inhibition of proliferative and inflammatory lung-vessel pathways can complement pathway-based vasodilators and sotatercept. TORREY phase 2 trial

Methodologies and Scientific Approaches

PAH researchers combine patient-derived blood, genetic, imaging, and right-heart-catheterization data with experiments in pulmonary artery endothelial cells, smooth-muscle cells, and precision-cut human lung slices. Animal studies commonly use monocrotaline and Sugen/hypoxia models in rats or mice because they produce elevated pulmonary pressures, right-ventricular strain, and remodeled small arteries; researchers then test whether a candidate treatment can reverse established disease rather than only prevent it. BMPR2 mRNA nanoparticle study AURKB inhibition study

Newer platforms aim to make treatment more precise: inhaled drugs concentrate exposure in the lung, lipid nanoparticles can carry mRNA toward pulmonary endothelial cells, and gene-edited large-animal models can better evaluate therapies before first-in-human studies. Biomarkers such as NT-proBNP, pulmonary vascular resistance, exercise capacity, risk scores, and right-ventricular imaging remain central for determining whether a therapy is truly changing disease trajectory. 2022 ESC/ERS Guidelines Gene-edited BMPR2 sheep model

Leading Institutions and Funding

The field is driven by international PAH referral centers and trial networks, including centers participating in STELLAR, ZENITH, HYPERION, TORREY, and PROSERA; key commercial developers include Merck, which acquired Acceleron and sponsors the sotatercept program, and Gossamer Bio, sponsor of seralutinib. STELLAR trial record ZENITH trial record PROSERA phase 3 study

Public and nonprofit support remains important for earlier-stage work. The U.S. National Heart, Lung, and Blood Institute funds pulmonary-hypertension research, including lung-vascular biology and pediatric pulmonary-hypertension collaborations. NHLBI pulmonary-hypertension research The Pulmonary Hypertension Association’s current programs include innovation awards of up to $120,000 over two years, early-career bridge awards of up to $65,000, and pediatric pilot awards of up to $65,000. PHA research grants

Strengths, Limitations, and Challenges

The main strength of current research is its shift from symptom-oriented vasodilation toward the biological processes that narrow pulmonary arteries: defective BMP signaling, inflammation, fibrosis, abnormal cell proliferation, metabolic dysfunction, and right-ventricular injury. Sotatercept’s phase 3 results provide the strongest evidence so far that intervening in remodeling biology can substantially reduce severe clinical events even in high-risk disease. ZENITH trial

However, improved outcomes do not yet establish reversal of every diseased vessel, restoration of normal right-heart biology, or a durable cure after treatment stops. Sotatercept requires ongoing dosing and can cause erythrocytosis, thrombocytopenia, and serious bleeding; the FDA reported serious bleeding in 4% of sotatercept-treated participants versus 1% of placebo recipients in the pivotal trial. FDA Winrevair snapshot Gene and RNA therapies face additional challenges: delivering treatment selectively to the correct lung cells, avoiding immune or off-target effects, achieving durable expression, proving benefit in diverse PAH subtypes, and manufacturing therapies at a cost that permits broad access. BMPR2 mRNA nanoparticle study Emerging PAH therapeutic landscape

Outlook and Future Directions

As of August 8, 2026, PAH is not close to a proven cure, but the field is closer to disease modification than it was in 2020. The most important milestones to watch are long-term sotatercept outcomes, results and regulatory progress from anti-remodeling inhaled therapies such as seralutinib, and the first safe human studies of lung-targeted BMPR2 replacement or other nucleic-acid therapies. A realistic cure would likely require durable correction of pulmonary vascular remodeling and preservation or recovery of right-ventricular function, potentially through individualized combinations rather than a single universal treatment. Emerging PAH therapeutic landscape BMPR2 mRNA nanoparticle study

References

Don't see your disease? Request a report